SMALL – Mr Stuart McIntosh, Clinical Senior Lecturer in Surgical Oncology, Queen’s University Belfast
This talk will cover:
• Rationale for minimally invasive treatment of small, biologically favourable breast cancer.
• Background to SMALL trial.
• SMALL trial design and eligibility criteria.
Stuart McIntosh is a Clinical Senior Lecturer in Surgical Oncology at Queen’s University in Belfast, and consultant breast surgeon at Belfast City Hospital. He graduated from Edinburgh University in 1993, completing general surgical training in the North-East of Scotland, moving to Belfast in 2009, and to an academic position in 2015. He is an experienced breast cancer clinical trialist, having contributed to numerous trials in early breast cancer, with a particular emphasis on neoadjuvant, peri-surgical and treatment de-escalation studies. He is the Chief Investigator for the UK HTA-funded SMALL trial, a national phase III multicentre study comparing standard surgery with vacuum-assisted excision for the treatment of small screen-detected breast cancers. His translational research interests include breast cancer risk, genetic predisposition and mechanisms of tumourigenesis, and the DNA damage immune response in breast cancer. As a member of the both the UK National Cancer Research Institute Breast Clinical Studies Group and the NCRI Strategic Advisory Group he has an excellent overview of the portfolio of clinical and translational breast cancer research in the UK. In his role as the Royal College of Surgeons Breast Surgical Specialty Lead, he is responsible for supporting the development and delivery of breast cancer trials nationally, with a specific emphasis on surgical studies. Stuart is also Clinical Director for the Northern Ireland Cancer Trials Network, responsible for overseeing delivery of cancer clinical research across the five cancer hospitals in Northern Ireland.
LORIS and Nostra trial where we are – Dr Matthew Wallis, Consultant Radiologist, Cambridge
Dr Matthew Wallis was the Quality Assurance Radiologist for the West Midlands Breast Screening Programme for 12 years. He moved to Cambridge in November 2007. President European Society of Breast Imaging 2008-2010. His major research interest in developing methods to monitor and audit screening performance has informed standard setting in image quality, radiology and surgery across the world. He has published on all aspects of optimising diagnosis and care of breast disease. His long-standing interest in DCIS has led to development of the UK de-escalation trials. Chief Investigator of LORIS (Low risk DCIS trial).
